A novel drug combination

for treating cancer

About us

Tiltan Pharma is an Israeli biopharmaceutical company, established in 2006, that developed a proprietary anti-angiogenic and immune modulatory platform technology...

Tiltan's drug combination

Tiltan has developed a proprietary combinatorial drug therapy that consists of metronomic chemotherapy together with...

Clinical trials

Tiltan Pharma started its first human trial with its investigational product (IP), phase 1/2, on November 2006 in Sheba Medical Center, Israel. The main objective...

Scientific publications

TL-118—anti-angiogenic treatment in pancreatic cancer: a case report.